Do analysts rate QUCY or ANIX?

Anixa Biosciences has a consensus price target of $8.50, indicating a potential upside of 200.35%. Given Anixa Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Anixa Biosciences is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Anixa Biosciences 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Is QUCY or ANIX more profitable?

Mainz Biomed's return on equity of 0.00% beat Anixa Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Mainz Biomed N/A N/A N/A Anixa Biosciences N/A -71.12% -62.88%

Does the media prefer QUCY or ANIX?

In the previous week, Anixa Biosciences had 1 more articles in the media than Mainz Biomed. MarketBeat recorded 5 mentions for Anixa Biosciences and 4 mentions for Mainz Biomed. Anixa Biosciences' average media sentiment score of 0.76 beat Mainz Biomed's score of 0.48 indicating that Anixa Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mainz Biomed 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Anixa Biosciences 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate TELO or QUCY?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is TELO or QUCY more profitable?

Mainz Biomed's return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Telomir Pharmaceuticals N/A -201.23% -172.71% Mainz Biomed N/A N/A N/A

Does the media prefer TELO or QUCY?

In the previous week, Mainz Biomed had 2 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 4 mentions for Mainz Biomed and 2 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 1.31 beat Mainz Biomed's score of 0.48 indicating that Telomir Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telomir Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mainz Biomed 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate RANI or QUCY?

Rani Therapeutics currently has a consensus target price of $8.75, suggesting a potential upside of 1,051.32%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Rani Therapeutics is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rani Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is RANI or QUCY more profitable?

Mainz Biomed's return on equity of 0.00% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rani Therapeutics N/A -206.46% -83.95% Mainz Biomed N/A N/A N/A

Does the media favor RANI or QUCY?

In the previous week, Mainz Biomed had 2 more articles in the media than Rani Therapeutics. MarketBeat recorded 4 mentions for Mainz Biomed and 2 mentions for Rani Therapeutics. Rani Therapeutics' average media sentiment score of 0.93 beat Mainz Biomed's score of 0.48 indicating that Rani Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rani Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mainz Biomed 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer QUCY or VRCA?

Verrica Pharmaceuticals has a consensus price target of $14.50, suggesting a potential upside of 129.07%. Given Verrica Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Verrica Pharmaceuticals is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Verrica Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media refer more to QUCY or VRCA?

In the previous week, Mainz Biomed had 2 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 4 mentions for Mainz Biomed and 2 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 0.94 beat Mainz Biomed's score of 0.48 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mainz Biomed 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Verrica Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ETHZ or QUCY?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Flag Ship Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is ETHZ or QUCY more profitable?

Mainz Biomed's return on equity of 0.00% beat Flag Ship Acquisition's return on equity. Company Net Margins Return on Equity Return on Assets Flag Ship Acquisition N/A -185.71% -83.12% Mainz Biomed N/A N/A N/A

Mainz Biomed (QUCY) Competitors

$1.56 -0.04 (-2.19%)

As of 12:59 PM Eastern

Compare

QUCY vs. ANIX, TELO, RANI, VRCA, and ETHZ

Should you buy Mainz Biomed stock or one of its competitors? MarketBeat compares Mainz Biomed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mainz Biomed include Anixa Biosciences (ANIX), Telomir Pharmaceuticals (TELO), Rani Therapeutics (RANI), Verrica Pharmaceuticals (VRCA), and Flag Ship Acquisition (ETHZ). These companies are all part of the "pharmaceutical products" industry.

How does Mainz Biomed compare to Anixa Biosciences?

Mainz Biomed (NASDAQ:QUCY) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Mainz Biomed has a beta of 2.17, indicating that its share price is 117% more volatile than the broader market. Comparatively, Anixa Biosciences has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market.

Anixa Biosciences has lower revenue, but higher earnings than Mainz Biomed. Anixa Biosciences is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$537.08K	42.58	-$16.21M	-$47.60	N/A
Anixa Biosciences	N/A	N/A	-$10.93M	-$0.31	N/A

In the previous week, Anixa Biosciences had 1 more articles in the media than Mainz Biomed. MarketBeat recorded 5 mentions for Anixa Biosciences and 4 mentions for Mainz Biomed. Anixa Biosciences' average media sentiment score of 0.76 beat Mainz Biomed's score of 0.48 indicating that Anixa Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mainz Biomed	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anixa Biosciences	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

29.1% of Anixa Biosciences shares are owned by institutional investors. 3.1% of Mainz Biomed shares are owned by insiders. Comparatively, 26.4% of Anixa Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Mainz Biomed's return on equity of 0.00% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
Anixa Biosciences	N/A	-71.12%	-62.88%

Anixa Biosciences has a consensus price target of $8.50, indicating a potential upside of 200.35%. Given Anixa Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Anixa Biosciences is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Anixa Biosciences beats Mainz Biomed on 9 of the 14 factors compared between the two stocks.

How does Mainz Biomed compare to Telomir Pharmaceuticals?

Telomir Pharmaceuticals (NASDAQ:TELO) and Mainz Biomed (NASDAQ:QUCY) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Mainz Biomed's return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%
Mainz Biomed	N/A	N/A	N/A

Telomir Pharmaceuticals has higher earnings, but lower revenue than Mainz Biomed. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A
Mainz Biomed	$537.08K	42.58	-$16.21M	-$47.60	N/A

In the previous week, Mainz Biomed had 2 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 4 mentions for Mainz Biomed and 2 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 1.31 beat Mainz Biomed's score of 0.48 indicating that Telomir Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telomir Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mainz Biomed	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Telomir Pharmaceuticals has a beta of -0.24, suggesting that its share price is 124% less volatile than the broader market. Comparatively, Mainz Biomed has a beta of 2.17, suggesting that its share price is 117% more volatile than the broader market.

Summary

Mainz Biomed beats Telomir Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Mainz Biomed compare to Rani Therapeutics?

Rani Therapeutics (NASDAQ:RANI) and Mainz Biomed (NASDAQ:QUCY) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

30.2% of Rani Therapeutics shares are owned by institutional investors. 26.7% of Rani Therapeutics shares are owned by company insiders. Comparatively, 3.1% of Mainz Biomed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Mainz Biomed's return on equity of 0.00% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-206.46%	-83.95%
Mainz Biomed	N/A	N/A	N/A

Rani Therapeutics has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, Mainz Biomed has a beta of 2.17, indicating that its stock price is 117% more volatile than the broader market.

In the previous week, Mainz Biomed had 2 more articles in the media than Rani Therapeutics. MarketBeat recorded 4 mentions for Mainz Biomed and 2 mentions for Rani Therapeutics. Rani Therapeutics' average media sentiment score of 0.93 beat Mainz Biomed's score of 0.48 indicating that Rani Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rani Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mainz Biomed	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rani Therapeutics currently has a consensus target price of $8.75, suggesting a potential upside of 1,051.32%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Rani Therapeutics is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Mainz Biomed has lower revenue, but higher earnings than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$3.17M	29.71	-$29.67M	-$0.41	N/A
Mainz Biomed	$537.08K	42.58	-$16.21M	-$47.60	N/A

Summary

Rani Therapeutics beats Mainz Biomed on 8 of the 15 factors compared between the two stocks.

How does Mainz Biomed compare to Verrica Pharmaceuticals?

Mainz Biomed (NASDAQ:QUCY) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

Mainz Biomed has a beta of 2.17, indicating that its stock price is 117% more volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market.

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 3.1% of Mainz Biomed shares are held by company insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Mainz Biomed has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -47.97%. Mainz Biomed's return on equity of 0.00% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%

Mainz Biomed has higher earnings, but lower revenue than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$537.08K	42.58	-$16.21M	-$47.60	N/A
Verrica Pharmaceuticals	$35.58M	3.06	-$17.89M	-$1.03	N/A

Verrica Pharmaceuticals has a consensus price target of $14.50, suggesting a potential upside of 129.07%. Given Verrica Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Verrica Pharmaceuticals is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Mainz Biomed had 2 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 4 mentions for Mainz Biomed and 2 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 0.94 beat Mainz Biomed's score of 0.48 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mainz Biomed	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Verrica Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Mainz Biomed and Verrica Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Mainz Biomed compare to Flag Ship Acquisition?

Flag Ship Acquisition (NASDAQ:ETHZ) and Mainz Biomed (NASDAQ:QUCY) are both small-cap manufacturing companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Flag Ship Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

4.1% of Flag Ship Acquisition shares are owned by institutional investors. 15.1% of Flag Ship Acquisition shares are owned by company insiders. Comparatively, 3.1% of Mainz Biomed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Flag Ship Acquisition has a beta of 1.17, suggesting that its share price is 17% more volatile than the broader market. Comparatively, Mainz Biomed has a beta of 2.17, suggesting that its share price is 117% more volatile than the broader market.

Mainz Biomed's return on equity of 0.00% beat Flag Ship Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Flag Ship Acquisition	N/A	-185.71%	-83.12%
Mainz Biomed	N/A	N/A	N/A

Flag Ship Acquisition has higher revenue and earnings than Mainz Biomed. Flag Ship Acquisition is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Flag Ship Acquisition	$4.11M	25.81	-$6.17M	-$159.65	N/A
Mainz Biomed	$537.08K	42.58	-$16.21M	-$47.60	N/A

In the previous week, Mainz Biomed had 4 more articles in the media than Flag Ship Acquisition. MarketBeat recorded 4 mentions for Mainz Biomed and 0 mentions for Flag Ship Acquisition. Mainz Biomed's average media sentiment score of 0.48 beat Flag Ship Acquisition's score of 0.00 indicating that Mainz Biomed is being referred to more favorably in the news media.

Company	Overall Sentiment
Flag Ship Acquisition	Neutral
Mainz Biomed	Neutral

Summary

Mainz Biomed beats Flag Ship Acquisition on 9 of the 13 factors compared between the two stocks.

Get Mainz Biomed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QUCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QUCY vs. The Competition

Export

Metric	Mainz Biomed	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$22.80M	$1.01B	$4.43B	$12.57B
Dividend Yield	N/A	4.84%	13.72%	6.21%
P/E Ratio	-0.03	1.51	23.52	24.73
Price / Sales	42.58	114.45	152.55	110.43
Price / Cash	N/A	20.06	36.62	36.96
Price / Book	22.29	8.08	13.22	6.54
Net Income	-$16.21M	-$3.83M	$114.87M	$336.74M
7 Day Performance	4.70%	1.99%	0.80%	1.34%
1 Month Performance	-39.06%	1.35%	0.51%	0.45%
1 Year Performance	N/A	50.79%	12.44%	30.94%

Mainz Biomed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QUCY Mainz Biomed	0.3083 of 5 stars	$1.57 -2.2%	N/A	N/A	$22.87M	$537.08K	N/A	30
ANIX Anixa Biosciences	4.291 of 5 stars	$2.91 flat	$8.50 +192.1%	-11.5%	$99.00M	$210K	N/A	5	Positive News Gap Up High Trading Volume
TELO Telomir Pharmaceuticals	0.6421 of 5 stars	$1.42 flat	N/A	-18.3%	$97.67M	N/A	N/A	1	Positive News High Trading Volume
RANI Rani Therapeutics	2.3482 of 5 stars	$0.78 flat	$8.75 +1,018.4%	+38.5%	$96.92M	$1.63M	N/A	110	News Coverage
VRCA Verrica Pharmaceuticals	3.002 of 5 stars	$5.63 flat	$14.50 +157.5%	+24.4%	$96.72M	$35.58M	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QUCY) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mainz Biomed (QUCY) Competitors

QUCY vs. ANIX, TELO, RANI, VRCA, and ETHZ

How does Mainz Biomed compare to Anixa Biosciences?

Summary

How does Mainz Biomed compare to Telomir Pharmaceuticals?

Summary

How does Mainz Biomed compare to Rani Therapeutics?

Summary

How does Mainz Biomed compare to Verrica Pharmaceuticals?

Summary

How does Mainz Biomed compare to Flag Ship Acquisition?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QUCY vs. The Competition

Mainz Biomed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mainz Biomed (QUCY) Competitors

QUCY vs. ANIX, TELO, RANI, VRCA, and ETHZ

How does Mainz Biomed compare to Anixa Biosciences?

Which has more volatility and risk, QUCY or ANIX?

Which has higher earnings and valuation, QUCY or ANIX?

Does the media prefer QUCY or ANIX?

Do insiders and institutionals believe in QUCY or ANIX?

Is QUCY or ANIX more profitable?

Do analysts rate QUCY or ANIX?

Summary

How does Mainz Biomed compare to Telomir Pharmaceuticals?

Do analysts rate TELO or QUCY?

Is TELO or QUCY more profitable?

Which has better valuation & earnings, TELO or QUCY?

Does the media prefer TELO or QUCY?

Which has more volatility & risk, TELO or QUCY?

Summary

How does Mainz Biomed compare to Rani Therapeutics?

Do institutionals and insiders hold more shares of RANI or QUCY?

Is RANI or QUCY more profitable?

Which has more volatility & risk, RANI or QUCY?

Does the media favor RANI or QUCY?

Do analysts rate RANI or QUCY?

Which has preferable valuation & earnings, RANI or QUCY?

Summary

How does Mainz Biomed compare to Verrica Pharmaceuticals?

Which has more volatility & risk, QUCY or VRCA?

Do insiders and institutionals hold more shares of QUCY or VRCA?

Is QUCY or VRCA more profitable?

Which has better earnings & valuation, QUCY or VRCA?

Do analysts prefer QUCY or VRCA?

Does the media refer more to QUCY or VRCA?

Summary

How does Mainz Biomed compare to Flag Ship Acquisition?

Do analysts recommend ETHZ or QUCY?

Do insiders & institutionals hold more shares of ETHZ or QUCY?

Which has more risk & volatility, ETHZ or QUCY?

Is ETHZ or QUCY more profitable?

Which has better valuation and earnings, ETHZ or QUCY?

Does the media refer more to ETHZ or QUCY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QUCY vs. The Competition

Mainz Biomed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools